Story perspectives

Pharma Faces $171 Billion Patent Cliff by 2030

12/20/2025

28 3

Summary

Story summary

Between 2025 and 2030, the pharmaceutical industry faces a patent cliff with US$171 billion in revenue at risk as major drugs lose exclusivity.
The shift will increase competition from generics and biosimilars, reducing pricing power and pressuring research budgets.
US drug makers face a challenging political landscape, as the Biosecure Act adds uncertainty.
Analysts warn these changes are approaching rapidly, and the industry must replace aging blockbusters to stay profitable.

1 of 1

Story summary

Between 2025 and 2030, the pharmaceutical industry faces a patent cliff with US$171 billion in revenue at risk as major drugs lose exclusivity.
The shift will increase competition from generics and biosimilars, reducing pricing power and pressuring research budgets.
US drug makers face a challenging political landscape, as the Biosecure Act adds uncertainty.
Analysts warn these changes are approaching rapidly, and the industry must replace aging blockbusters to stay profitable.